Eric Gulve, PhD. joined BioGenerator in 2007 following a 14 year career in the pharmaceutical industry. In 2009 he assumed overall leadership of BioGenerator. His responsibilities have expanded to include overall strategic direction, expansion of programs and services, oversight of the organizational budget, community outreach, regional collaborations, and service on the Board of Directors of several BioGenerator portfolio companies.

Prior to joining BioGenerator, Eric spent 14 years in the pharmaceutical industry focused on drug discovery research. From 2003 – 2007 he held various roles in local and global leadership teams in Cardiovascular research at Pfizer, and led laboratories working in the areas of thrombosis, hypertension, and metabolic disease. From 2000 – 2003, Eric was Associate Director of the Cardiovascular & Metabolic Diseases research group at Pharmacia Corporation, prior to Pharmacia's acquisition by Pfizer. From 1994 – 2000 he directed laboratory groups and served on leadership teams within G.D. Searle's Cardiovascular drug discovery research group, where he established the company's first diabetes research program. In addition to laboratory oversight and roles on therapeutic area discovery research leadership teams, Eric held other leadership roles, e.g. on drug discovery teams and new drug target identification/validation teams. In all three companies he held various roles on cardiovascular and metabolic disease therapeutic area in-licensing teams. Eric has worked collaboratively across different research lines, therapeutics areas, business units, and geographic sites. Over the course of his career he has supervised or mentored Ph.D., M.S. and B.A. scientists working inside and outside of his laboratories.

Eric received an A.B. in Chemistry from Occidental College (Los Angeles) and a Ph.D. in Physiology from Harvard University. He served as post-doctoral fellow and research faculty at Washington University School of Medicine, where his research focused on skeletal muscle metabolism and the molecular mechanisms which contribute to the beneficial effects of exercise in diabetes and other states characterized by defective glucose metabolism. He has worked directly or overseen the work of direct reports in a number of different fields including skeletal muscle carbohydrate and protein metabolism, diabetes, thrombosis, and hypertension. Eric has published over 40 peer-reviewed articles and has contributed to several book chapters and review articles. He continues to lecture periodically on the subjects of skeletal muscle metabolism, diabetes, and muscle protein turnover.

Dan Broderick has over 22 years of experience in the life sciences and venture capital industry. Prior to joining Prolog Ventures in 2007, Dan spent 7 years with Mason Wells Biomedical Fund as a Managing Director where he was responsible for all aspects of investment activities. While at Mason Wells, Dan served as a member of the Board of Directors of several portfolio companies including Gala Biotech, Mezzia, OpGen, Deltanoid Pharmaceuticals and ZyStor Therapeutics.

Prior to Mason Wells, Dan spent 18 years at Mayo Clinic in Rochester, Minnesota, where for 12 years he served as Director of the Office of Technology Commercialization. He has personally evaluated the commercial potential of hundreds of technologies in virtually every medical specialty. He has been directly responsible for negotiating and consummating over 100 medical technology commercialization agreements. He has experience with technology evaluation, market assessment, negotiations, academic institution technology transfer, and intellectual property management.

Dan played a key role in the launch of Mayo Clinic’s $25 million venture investing program. He co-founded and served on the Board of Directors of IntraTherapuetics, Inc., CNSoftware and Medintell, Inc. In 1994, Dan was honored with an appointment to the Staff of Mayo Clinic.

Dan is actively involved in the venture capital community on a regional and national level. He served on the Board of Directors of the National Venture Capital Association (NVCA). He has testified before the U.S. Congress on behalf of the NVCA; works on a number of NVCA committees, and Chaired the Research Committee. Dan is the founder of the Mid-America Healthcare Investor Network (MHIN) and currently serves as President of the organization. He also is the past President of the Wisconsin Biotechnology and Medical Device Association, sat on the Advisory Boards of the University of Minnesota’s Office of Business Development and BioGenerator in St. Louis, Missouri,. He also served as a member of the Board of Trustees for the Medical College of Wisconsin Research Foundation and the University of Wisconsin – Milwaukee Research Foundation.

Dan received a Bachelors Degree in Biology from Iowa State University in 1982. He has completed some graduate course work in Finance, Accounting and Marketing at Winona State University.

Dan is 49 years old, and married with three children. He enjoys fishing, woodworking and renaissance art.

Charlie Bolten was recruited to BioGenerator in July of 2009.

Charlie participates in all aspects of technology commercialization at BioGenerator. His specific responsibilities include the BioGenerator Spark Fund and BioGenerator Accelerator Labs programs, which he conceived of and directs. Charlie serves as the Commercialization Director of the St. Louis Regional i6 Project where he chairs the Project Core Team and leads all investment activity.

Since joining BioGenerator in 2009, Charlie has led 19 investments in 15 portfolio companies, typically participating in formation of the company and/or leading the first investment syndicate. Example portfolio companies include Confluence Life Sciences, Apse, Kypha, X-tend Energy, MediBeacon, Euclises and Array Bridge. Charlie serves on the Board of Directors for various portfolio companies.

At the time of his recruitment to BioGenerator, Charlie held the position of Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group, where he led a reverse pharmacology collaboration with PTC Therapeutics focusing on post-transcriptional regulation of T cell cytokines and was the Research Project Leader for small molecule discovery program targeting an effector T cell subtype-selective receptor.

Edward Hamati has over 11 years of experience in finance, business strategy, management consulting and laboratory research roles.  He joined BioGenerator in 2012 to focus on due diligence activities with an emphasis on the seed fund side.  Additionally, Edward provides strategic advisory services to current and potential portfolio companies and opportunities as they enter the due diligence process.

Before joining BioGenerator, Edward served at The Chi Rho Group, a private equity firm that functioned as the family investment arm of the Steward family, owners of World Wide Technology Inc.  Edward was responsible for review of new M&A opportunities, due diligence, government initiatives, and oversight of the existing investment portfolio.  He also oversaw special projects, including a Fortune 500 business intelligence initiative, a turnaround strategy for a consumer packaged goods firm, a health care supply chain initiative for the federal government, and development of an implementation plan for a Fortune 500 scale fulfillment firm.

Prior to his role at the Chi Rho Group, Edward worked for The Broadband Group, a management consulting firm focused on the telecom industry.  Edward founded the financial services platform for the company including the development of several proprietary financial models.  He was also responsible for drafting business plans and raising equity and debt financing to fund new telecom entities, startups and business development initiatives.  Additionally, he represented several Fortune 500 companies including large OEM players Hitachi Telecom and Alcatel Lucent.

Earlier in his career, Edward worked at the Center for Comparative Respiratory Biology and Medicine at UC Davis as a laboratory manager and scientist.  Research areas included analysis of viral infections on gene expression, tobacco smoke research, and various mucus secretion pathways, all within human and animal models.  Edward is a coauthor on several publications in Respiratory Medicine.

Edward has a BS in Cellular Biology from University of California, Davis.  He earned his MBA from California State University, Sacramento in Finance and Business Strategy and attended University of Oxford, United Kingdom as an attachment to his MBA with a focus in business strategy.  He also attended the Sacramento Entrepreneurship Academy, further enhancing his knowledge and experience in providing due diligence, business plan development and corporate start-up models.

Keryn has held executive leadership positions, recruiting and consulting for companies including those in:

• Medical Devices
• Pharmaceuticals
• IT
• Technology Transfer
• Materials Science and Engineering
• Veterinary Medicine

Keryn has experience running a materials science and engineering startup company, is skilled at scouting and assessing novel technologies for commercial viability, and at providing strategic investment, market entry, partnership, growth, and business development strategies and recommendations for businesses across industries.

Keryn also has extensive applied mathematics and statistics background, in addition to 7+ years of broad spectrum biomedical technical expertise, with a Ph.D. in Biology and Biomedical Sciences.

Crystal has over 7 years of experience in biomedical research with expertise in the fields of cancer and bone biology. She received a B.S. in Molecular Biology from Bradley University, where she was involved in animal physiology research for 4 years.  In 2011, Crystal received her Ph.D. in Molecular Cell Biology from Washington University in St. Louis. Crystal’s thesis research focused on analyzing the genetics of a mouse model for studying osteoclasts and the role of the ARF tumor suppressor in post-mitotic cells. During her academic career, she was also responsible for the critical review of scientific data spanning a broad spectrum of biomedical research.

Additionally, Crystal has held leadership positions for a consulting company that works with biotechnology start-ups. In this role, she focused on due diligence, market assessment, and interviewing key opinion leaders. Crystal joined BioGenerator as an investment analyst in 2013.

Harry Arader joined BioGenerator as Entrepreneur in Residence in September of 2011.

Prior to his recruitment, Harry was founder and President of The Centromere Group, a business development and strategy consultancy to the biotechnology and pharmaceutical industries. In addition to providing consulting services to a wide range of lifescience clients through the Centromere Group, Harry devoted time to start-up companies.

Since 2005, Harry has been an Independent Director of Midway Pharmaceuticals Inc., an early stage pharmaceutical company spun-out from the University of Chicago. Harry is currently Acting CEO of Midway Food Animal Sciences, a seed-stage company with transformative products that replace antibiotics used in food animals.

From 2003 – 2007, Harry cofounded, and acted as a Director; Chief Business Officer and Interim President of Nanodisc Inc. a nanotechnology-based drug delivery company. Beginning in 1998, Harry acted as Chief Business Officer and currently acts as Business Development Consultant to Orion Genomics LLC – a successful genomics-based, epigenetic discovery company in St. Louis MO. He also served as CEO for BioDisplay Technologies Inc., a directed evolution platform biotechnology company in Urbana Illinois from shortly after that company's inception in 1999 until it was sold to Abbott Laboratories in December 2001. In 1998, he was a Senior Business Advisor to Unimed Pharmaceuticals, a publicly traded pharmaceutical company that was sold to Solvay for a 6X appreciation in share value over the term of the engagement.

In economic development projects at the Centromere Group, in 1997-98 Harry wrote the "Illinois State Strategic Plan for the Biotechnology Industry". Based on the warm reception for the recommendations in this study, in 1998 he served on the transition team for former Illinois Governor George Ryan. He was one of the founders of IBIO (the Illinois Biotechnology Industry Organization) and launched the successful effort that resulted in bringing the BIO 2006 trade-show to Chicago. Harry was also the principle consultant to the University of Illinois during the design of Illinois Ventures, a seed and early-stage venture fund.

Harry was Chief Financial Officer of Millennium Pharmaceuticals Inc. where he was a key participant in the firm's IPO that raised $57 million. He was also a key driver of the $90 million acquisition of Chemgenics Pharmaceuticals. He built and led the Finance, Strategic Planning, Investor Relations, Materials Management and Facilities functions during a period of rapid company growth.

Prior to Millennium, Harry spent 10 years at Searle, the Pharmaceutical arm of Monsanto. As Managing Director of Searle Greater China in 1993-95, Harry had full P&L responsibility for all company operations there. Sales revenue quadrupled, and profitability tripled during Harry's tenure. Some of Harry's specific projects included the creation of a sales and marketing organization on the Chinese mainland, the negotiation of joint ventures with two Chinese companies and the streamlining of operations in Taiwan.

In 1992-93, as Searle's Vice President of International Marketing, Harry had extensive experiences in Europe and Asia. Among many other projects, he was instrumental in a co-promotion agreement for the launch of Searle's Arthrotec brand in Germany, which resulted in a 75% improvement in market share versus projections. Harry was also extensively involved in Searle's Japan operations, leading a product repositioning effort and the reorganization of the sales and marketing functions yielding a $70 million improvement in operating earnings.

In 1990, Searle Pharmaceuticals' Chairman, Dr. Sheldon Gilgore, selected Harry to serve as Executive Director of Strategic Planning. Reporting directly to the Chairman and as an advisory member of the Executive Management Committee, Harry organized and managed the annual strategic planning process. Harry was also a leader in Searle's successful public policy efforts that led to the elevation of Chairman Gilgore to the head of the industry trade association, PhRMA where he played an important role in dealing with the proposed Clinton Health Plan.

In his early days at Searle Harry focused on marketing and business development. As Product Director – GI/Anti-inflammatory Products he developed and implemented the launch plan for Cytotec, the innovative product for the prevention of ulcers associated with arthritis medications. As Associate Director of New Products, US, Harry led the efforts to in-license the Daypro and Ambien brands that went on to became Searle's number one and two revenue generators through most of the 1990s.

Prior to joining Searle, Harry held Sales and Marketing positions at Merck & Co. As Marketing Research Analyst, Harry built on his Pharmaceutical Sales Representative experiences as he headed up a team that developed the industry's first rigorously controlled promotion productivity testing capability.

In addition to his accomplishments in his professional life, Harry is very active in the arts. He is a musician (guitar) and songwriter. He also does visual art including watercolor, oil painting and chalk pastel. He has long been a supporter of a fast-growing Chicago theater company called Collaboraction, and was that organization's Board President from January 2003 – December 2004. Harry recently joined the board of the Ox-Bow, a 95 year- old summer school of art and artists' residency affiliated with the Art Institute of Chicago.

Harry's educational background includes an MBA in Marketing and Strategic Planning from the Wharton School ('83), and a BA in Cultural Anthropology from the State University of New York at Purchase ('76).

Joe has over 25 years of assembling and leading successful teams with diverse and aggressive objectives, such as the research and development of products and services, the optimization of business and manufacturing processes, the acquisition and integration of businesses, the strategic planning, marketing and sales growth of product lines, the improvement of partnerships and supply chains, or the launch of new products and services. Joe enjoys the challenges of removing obstacles to expand businesses.

Joe's experience has been in multiple industry sectors such as BioPharma, Information Technology, Private Equity, Medical Devices, Consumer Goods, Combination Products, Instrumentation, Pharmaceuticals, and Industrial Equipment. Joe's teams have been successful in the largest corporate environments as well as small, startup, or private ventures. He enjoys solving complex issues and facilitating good business decisions.

Joe received a Bachelor's of Science from the University of Illinois and a Master's of Business Administration from the Executive Program at Washington University. He is a member of Beta Gamma Sigma. He also completed a Global Entrepreneurship program at Rutgers University.

Tom joined BioGenerator in June 2012 as a Senior Entrepreneur in Residence to help build portfolio companies and to launch new companies. He is also the Chairman of the Board for Vasculox, Inc., a portfolio company with a biologic initially targeted for organ transplant rejection caused by ischemic reperfusion injury.

Tom possesses extensive biotechnology and pharmaceutical executive experience. He has worked in most therapeutic areas, including brands, generics, over-the-counter products, and biologics. His successes demonstrate leadership, empowerment of teams, and investor, Board/C level stakeholder influence skills. He has impacted strategic, commercial and implementation results in large, mid-market, and start-up companies. With Tom's core capabilities in strategy, identifying growth opportunities, spotting innovative product offerings, due diligence and execution, he has created over $30B in value and over $2B in new product offerings via business development, licensing, partnering, and M&A across 13 countries (including China and Japan). He is also an expert commercial and business development innovator, prospector and negotiator accomplished in closing deals with full integration with adaptive skills.

Tom's experience includes serial successes in growth driven markets requiring market-centric strategy and global commercial launches requiring market-tailored sales and marketing. He has been part of 8 global launches during his career including recent commercial leadership roles. Tom's global commercial knowhow includes initial go to market assessment and development of initial launch plans including strategic positioning, primary market research and pricing strategies. In addition, he has the benefit of successfully managing a full P&L within a 35 person biologic contract manufacturing start-up in a turnaround environment that required high level consultative sales and marketing.

His transformational mark has been felt across Monsanto/Searle/Pharmacia, Cardinal Health, KV Pharmaceuticals, and in his recent biologic start ups of Vasculox, Inc. and Cerenis Therapeutics. Tom has multiple Board roles and is also an experienced investor / analyst / communicator in various public settings.

Tom has a MBA from Northwestern Kellogg School of Management, with emphasis in sales and marketing, and a CPA with strong finance experiences from early in his career. In addition, he is a long-term member of the Licensing Executive Society and a Chicago Innovation Mentor.

Vijay Chauhan has over 23 years business management experience, comprised of 14 years within Life Sciences, Functional Foods/Nutrition spaces and 8 years in Management Consulting roles. Prior to joining BioGenerator as an EIR, Vijay was the Founder and CEO of Healthcare Consulting. He worked with a Microbial Biotech company to implement a business turnaround plan, develop a business plan and raise capital. He also provided acquisition and valuation advice to a Private Equity firm acquiring a nutrition company with a patented enzyme system to improve protein synthesis and amino acid absorption.

From 2001 to 2011, Vijay started two companies in the functional foods/nutraceutical and ag-biotech space and raised over $6 million in capital from Angel/VC and Strategic investors. As CEO of Clinical Products/ExtendSnacks, Vijay built a profitable Diabetes and Obesity Nutrition Company. He developed a broad range of nutrition products in the diabetes category built around 17 patents and 6 clinical studies. The company achieved successful national US retail distribution across Drug, Mass, Food and Etailer channels and expanded into 15 countries by building country by country distributor network. Under a second brand, Vijay built a specialty weight management business and program in physician weight management market. The company implemented a highly successful direct distribution and mass retail distribution strategy in the US leveraging Social Media to build high engagement relationships with consumers, healthcare professionals and media.

From 1996 to 2000, Vijay worked at Monsanto in St. Louis, MO. As Vice President, General Manager, Nutrition and Consumer Sector, Vijay was responsible for Strategy and Business Development, Sales, Consumer and Health Care Professional Marketing, PR, Regulatory and Manufacturing of a new business unit with $40 million annual budget and 15 person commercial team. He co-led an 80 person R&D team. His team developed strategy and business plans to launch two breakthrough nutriceutical products with $400 million revenue potential, 75% gross margins and 25-35% operating margins. The team assessed over 40 technology licensing opportunities and 10 global nutriceutical acquisition targets and successfully completed 5 agreements. He co-led the effort to forge an alliance with global OTC/pharmaceutical, food companies and biotech venture capital syndicates securing term sheet for $65 million investment.

From 1988 to 1996, Vijay worked at two management consulting companies in the Boston area. As an Officer of Cap Gemini/Gemini Consulting, Vijay sold and implemented large-scale business turnaround and transformation projects resulting in sustainable change and bottom-line benefits for clients across multiple industries. He sold over $20 million and managed 50 consultants over 3 years.

Vijay has an Undergraduate Degree in Mechanical Engineering from the Indian Institute of Technology (IIT Madras) and a Master's in Computer Science from the University of Delaware.

Will Haines joined BioGenerator in 1Q 2013 as Entrepreneur in Residence (EIR) motivated to help launch new life science companies within the St. Louis Region.

Since 2001, Will has held a variety of positions in medical services, research and development within the pharmaceutical industry. His efforts herein have been in support of the development of novel medicines in the cardiovascular and oncology therapeutic space. More specifically, Will has served as a scientific resource to healthcare professionals administering portfolio agents and has acted as liaison between home office R&D colleagues and community as well as academic clinical researchers.  As Director-Medical Science Liaisons, Will has helped lead teams of field-based scientists in the support of late stage (phase II and phase III) clinical trials involving novel medicines. He has helped establish and maintain key partnerships within his organization that facilitate development and transfer of intellectual capital on disease therapy and product information through the medical liaison team, to their customer base and corporate R&D, regulatory, marketing and sales functions.

In addition to his scientific experience, Will has been heavily involved in leading, managing and facilitating teamwork and subsequent corporate progress. He has worked collaboratively across many functional areas in the pharmaceutical industry partnering with sales, marketing, clinical operations and senior leadership and has supported the development of programs and processes that enhance the capacity and capability of the workforce, including: employee selection, training, development, best practices and communications support.

Will received his BS from the University of Illinois and his PhD in pharmacologic and physiologic science from Saint Louis University. His doctoral work helped better characterize the structure and function of a family of ATP-gated ion channels involved in numerous physiological processes. In 2011, Will earned an MBA from Washington University Olin School of Business.

Alex’s professional career spans 20 years in academic and biopharmaceutical research where he has held numerous leadership and management roles.  As a scientific leader, he has directed multidiscipline teams and line organizations in collaboration with business units to formulate and execute strategic initiatives for new target discovery, drug discovery and clinical development.  His broad domestic and international management experience of people and projects has involved the support of research portfolios in multiple therapeutic areas including Inflammation, Infectious Diseases, and Oncology.  Alex has demonstrated success in translational research directing and delivering drug discovery projects from concept to Ph2 clinical development. Understanding the strength of collaborative relationships, Alex has often been recognized for his record of establishing, critically evaluating, and overseeing research collaborations for business development with Biopharmaceutical Partners, Research Institutes and Academic Medical Centers. 

Earlier in his career Alex led research groups with two Biotechnology companies Human Genome Sciences, Inc. (HGSI) and Protein Design Labs, Inc. (PDLI).  While at HGSI, a company specializing in the use of human DNA sequences to develop protein & antibody drugs, his group supported new target discovery and high-throughput assay development for corporate collaborators MedImmune, Inc (a subsidiary of AstraZeneca) and Pharmacia Corporation by delivering over 100 target proteins for vaccine and drug discovery.  As a Research Director at PDLI, a company that pioneered monoclonal antibody humanization for human therapeutic use, he managed a corporate collaboration with Eli Lilly and his group successfully met collaboration milestones delivering 2 drug discovery programs.  Alex was recruited to join Pharmacia and later Pfizer Corporation, two global leaders in pharmaceutical drug discovery that developed blockbuster drugs Celebrex and Lipitor.  During his career in the pharmaceutical industry, Alex led drug discovery groups, project teams, managed research portfolios for multiple therapeutic areas including Inflammation, Infectious Diseases, and Oncology.  During this time the teams he led successfully delivered numerous drug discovery projects from idea to clinical development.

Alex received a B.S. in Microbiology from the University of Maryland, College Park, and a Ph.D. in Microbiology and Immunology from the Uniformed Services University of the Health Sciences and an undergraduate.  He conducted his post-doctoral training at Stanford University School of Medicine.  He is currently, President of AXulting LLC a life-science and clinical research consulting firm as well as Managing Director of MetaCROM Services, LLC a CRO marketing solutions company.

Nandini Kishore, Ph.D., joined BioGenerator as an Entrepreneur in Residence in 2012.

Nandini has 25 years of experience in Drug Discovery, Development and Translational Medicine and has over fifty scientific publications. Currently, an Independent consultant, she maintains active interactions with Drug Discovery and Development teams both nationally and internationally in the Pharmaceutical and Biotechnology companies, and serves on the scientific advisory board of several start-up Life-Science companies globally.

Nandini has led drug discovery groups in the Inflammation research unit of Pfizer Global Research and Development. Her group was responsible for delivering new drug candidates from idea to clinical proof of concept (POC) including both small molecules and biologics. Additionally, she provided research leadership for a late stage drug candidate, a small molecule inhibitor of Janus family of kinases working closely with the Clinical and Regulatory teams. This drug candidate has completed global Phase III clinical trials for Rheumatoid Arthritis and has been submitted for Regulatory review by the FDA.

Nandini received her B.Sc and M.Sc from the University of Delhi, India and Ph.D from the University of Texas at Austin, in Biochemistry and Cell Biology. Following postdoctoral training in Washington University Medical School in St. Louis in the Departments of Biochemistry and Genetics, she joined Monsanto/Searle in 1986, as a Research Scientist. Monsanto/Searle merged with Pharmacia in 2000 and subsequently with Pfizer in 2003. Nandini has held positions of increasing responsibility during this transition and most recently served as an Executive Director in the Inflammation Research Division in St. Louis.

During her tenure in the Monsanto/Searle/ Pharmacia/Pfizer, Nandini made important contributions to multiple therapeutic areas including Infectious Diseases, Oncology, Allergy and Respiratory and Inflammation/Immunology. She has led many early and late stage projects, including large interdisciplinary project teams located in multiple geographic locations and has advanced drug candidates into the clinic. Examples include HIV protease inhibitors, metalloproteinase inhibitors for Oncology and kinase inhibitors for Rheumatoid Arthritis and other Autoimmune Diseases. She has several patents and has authored over 50 publications.

Alan MacInnes joined BioGenerator as an Entrepreneur in Residence (EIR) in May 2012. In this role, Alan will use his extensive pharmaceutical industry experience to assist with the creation and growth of new life science companies that have received or are strong candidates for BioGenerator funding, while learning the business aspects required to be a successful entrepreneur. Prior to joining the EIR program, Alan worked as a visiting professional with BioGenerator and successfully helped create a new BioGenerator company, Companion Pharma Inc. (CPI) which was recently incorporated and will develop proprietary pet-friendly formulations of drugs for companion animals through the FDAs NADA process. Alan holds the role of Vice President of technical and clinical development with CPI.

Prior to joining BioGenerator, Alan spent 19 years in the pharmaceutical industry as a research and development scientist and project team leader with Pfizer Inc. both in the United Kingdom and the United States. During this period, Alan led projects and laboratories at all phases of the drug discovery and development continuum from new drug target validation to human phase 2 clinical proof of concept. At Pfizer, Alan participated in the identification of 10 drug candidates for human clinical development.

From 2007 – 2011 Alan was Associate Research Fellow and Research Project Leader in the Pfizer Indications Discovery Unit whose remit was to repurpose drug candidates within the Pfizer development portfolio for use in secondary disease indications. During this time Alan led two high-profile phase 2 clinical projects for acute coronary syndromes and dyslipidemia, reviewed and nominated numerous potential new drug opportunity ideas for diabetes and obesity as the therapeutic area expert and liaison, and built an obesity research laboratory capability from scratch.

In 2003 Alan transferred from the UK to the US with Pfizer following their acquisition of the Pharmacia Corporation and took a role as project and laboratory leader in the cardiovascular and metabolic diseases research group in St. Louis. During this period he led and contributed to projects targeting hypertension, thrombosis, diabetes and metabolic disease. He also served on new drug target identification/validation teams and cross functional licensing leadership teams.

From 1992 – 2003 Alan conducted and led research teams in the areas of thrombosis, atherosclerosis, vascular inflammation, hypertension and skeletal/cardiac metabolism within the cardiovascular research group at Pfizer in the UK.

During his career at Pfizer Alan led several collaborations with leading academic medical centers; he also performed due diligence for potential product licensing and strategic alliance opportunities. He has supervised, managed and mentored numerous PhD, MSc and BSc scientists.

Alan received his BSc (Hons) degree in Pharmacology from the University of Sunderland School of Pharmacy and has published more than 20 peer-reviewed articles during his career.

Dr. McCarter was the founder, President, and Chief Scientific Officer of Divergence, Inc., a world leader in the application of genomics and informatics to agriculture and infectious disease. The Company’s discoveries led to three products now in development in agrochemistry, veterinary therapeutics, and diagnostics. Divergence raised over $20 million in private equity and venture capital and achieved a successful exit in 2011 when it was acquired by Monsanto Company which has advanced its seed treatment to phase II in its technology pipeline. Dr. McCarter is currently an EIR with Monsanto Growth Ventures, an initiative by the company to invest in start-ups that have potential to create transformative tools and technologies for farmers. He is also an Adjunct Professor of Genetics at Washington University School of Medicine and an author of over 50 scientific publications. Dr. McCarter completed his medical and doctoral training at Washington University and graduated magna cum laude from Princeton University. He is the recipient of the Innovation Award from the Academy of Science of St. Louis and a Crown Fellow of the Aspen Institute

Craig Morley recently joined the BioGenerator and brings with him over 25 years’ experience in the pharmaceutical, biotech, life sciences, medical device and diagnostics industries.  Craig is an accomplished executive with domestic and international experience in operations, P&L management, R&D, sales and marketing involving both start-up and growth organizations.  He has held numerous senior level positions at EAG Life Sciences, Transposagen Biopharmaceuticals, Merck/Millipore, Covance, bioMerieux, and Eli Lilly & Co. 

Most recently, he was responsible for the operations, business development, and marketing activities at EAG Life Science, a contract research organization (CRO) in St. Louis, MO, specializing in regulated bio analytical and analytical chemistry testing for the pharmaceutical and medical device industries.  Previously, he was the VP of Sales and Marketing for Transposagen Biopharmaceuticals, a privately held biotech company in Lexington, KY, developing and distributing genetically engineered animal models, cell lines, stem cells, and cutting-edge research tools. 

From 2007 through 2011, Craig served as the Global Managing Director of Biopharma Services at Millipore, with responsibility for services in St. Charles, MO and Oxford, UK.  He built a high growth, global CRO organization specializing in the support and development of large molecule biotech compounds.  With full P&L responsibilities, he successfully built the brand, added new services, and spearheaded expansion efforts.  Under his leadership and guidance, the business grew over 380% in four years.

From 2004 through 2007, he was employed by Covance, Madison, WI as their Global Marketing Director-Toxicology, providing leadership in strategic marketing efforts that resulted in over 60% revenue growth in three years.  He spearheaded and launched several new global service initiatives for safety pharmacology, inhalation, ocular, and general toxicology.  He was also responsible for the integration of industry leading strategic business models that led to multiple large contracts.

From 1995 through 2007, Craig held various senior level leadership roles at bioMerieux, a large international medical diagnostic company located in Lyon, France.  His various assignments included sales, marketing, program management, and business development at their US and European operations.   In the U.S., he led the development of TheraTrac, an innovative software program that integrated antimicrobial data with antibiotic therapy.  Craig was transferred to the German subsidiary and successfully launched the VITEK II system while providing commercial oversight.  After his assignment in Germany, Craig was promoted to the Global Marketing Team based in Lyon, France.   He successfully repositioned the VIDAS HIV DUO which improved sales from single digit growth to over 30% growth.  He launched the VIDAS emergency panel that drove sales of multiple immunoassays and the VIDAS system.  Craig was promoted to Program Director of the newly acquired Hemostasis business where he managed multiple R&D projects for the development of the product line.

He began his career with Eli Lilly & Company, Indianapolis, IN, in various sales and marketing roles from 1987 through 1995. During his sales career, Craig routinely finished in the top 5% of his peers as a sales representative and sales manager.  He was promoted into the International Cardiovascular Marketing Department where he was part of a team that successfully launched the first GPIIb/IIIa inhibitor - ReoPro (abciximab). 

With over 25 years of experience, Craig brings an abundance of knowledge and expertise to his role as Senior Entrepreneur in Residence at the BioGenerator.   He is a registered pharmacist with a pharmacy degree from the St. Louis College of Pharmacy.

Cheryl Watkins-Moore, D.P.M., joined BioGenerator as an Entrepreneur in Residence in 2012.

Dr. Cheryl Watkins-Moore is a highly versatile and visionary Business Leader experienced in P&L management, marketing, sales, integration, and restructuring. She is skilled at the effective design and execution of transformational strategic business and marketing plans that enhance brand position, operations, increased revenue and maximized return on investment. A leader at managing outstanding teams that work together to implement strategies that set and maintain high levels of performance and collaboration, she is highly proficient in crafting comprehensive initiatives which increase revenue. 

Dr. Moore most recently served as Vice President/General Manager for the Integrated Biomarker Solutions business initiative of EMD Millipore, the U.S. subsidiary of Merck KGaA. She led inter- divisional and cross-divisional teams from Pharmaceutical, Life Science and Discovery/ Development businesses focused on developing portfolio offerings of product/service solutions from across Merck’s businesses for the biomarker and diagnostics markets. Prior to this role, she served as Vice President/General Manager for EMD Merck Analytics Division; a $100M + chemical and specialty analytics business where she had full P&L responsibility and managed marketing, sales, technical service, pricing and distribution organizations. She implemented best practice business processes turning around this business division from a failing entity to a profitable sustainable organization.

Dr. Moore also has experience in the start-up environment, heading up the U.S. Marketing organization of a Swedish-based biotech company, Biora Inc.  While at this organization, she implemented strategies to successfully achieve 50% target market penetration in two years thereby making the U.S. subsidiary the top contributor for the entire organization.  Dr. Moore was selected to become a member of Biora’s Corporate International Marketing Board coordinating U.S. and international marketing while directly involved with the global management of marketing/sales issues, product development, and corporate/product positioning strategies.

Throughout her career, Dr. Moore has developed and implemented strategic initiatives for both the domestic and international markets. Since being selected by the Baxter/Allegiance Healthcare CEO to join the Executive Leadership Development Program early in her career, she has designed and developed management strategies that have brought new product offerings to market. Her experience encompasses global market penetration in both commodity and specialty products and services across diverse fields such as industry and laboratory chemicals, life sciences, biochemical products, and medical devices.

Dr. Moore holds a Masters of Business Management from the Kellogg School of Management, Northwestern University and a Bachelor of Arts degree in Biology from Fisk University. She is a Doctor of Podiatric Medicine, earning her degree from Illinois College of Podiatric Medicine. She has won several awards for her marketing innovations, including the American Marketing Association’s highest award, The Award of Excellence. She is a Board Member of both the Youth Learning Center, as well as the YWCA organization.  She is also a member of the Healthcare Business Women’s Association and is active in the St. Louis, MO chapter of Jack and Jill of America.